You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Investigational Drug Information for NRX-101


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug NRX-101?

NRX-101 is an investigational drug.

There have been 6 clinical trials for NRX-101. The most recent clinical trial was a Phase 2 trial, which was initiated on June 25th 2019.

The most common disease conditions in clinical trials are Depression, Bipolar Disorder, and Suicidal Ideation. The leading clinical trial sponsors are Target Health Inc., NeuroRx, Inc., and Bracket, Inc.

There are ten US patents protecting this investigational drug and five hundred and seventy-seven international patents.

Recent Clinical Trials for NRX-101
TitleSponsorPhase
NRX101 for Moderate Bipolar Depression and Suicidal IdeationBracket, Inc.Phase 2/Phase 3
NRX101 for Moderate Bipolar Depression and Suicidal IdeationStatistics Collaborative, Inc.Phase 2/Phase 3
NRX101 for Moderate Bipolar Depression and Suicidal IdeationTarget Health Inc.Phase 2/Phase 3

See all NRX-101 clinical trials

Clinical Trial Summary for NRX-101

Top disease conditions for NRX-101
Top clinical trial sponsors for NRX-101

See all NRX-101 clinical trials

US Patents for NRX-101

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
NRX-101 ⤷  Try a Trial Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system Chase Pharmaceuticals Corporation (Washington, DC) ⤷  Try a Trial
NRX-101 ⤷  Try a Trial Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy Watson Pharmaceuticals, Inc. (Corona, CA) ⤷  Try a Trial
NRX-101 ⤷  Try a Trial Compositions and methods for transdermal oxybutynin therapy Watson Laboratories, Inc. (Salt Lake City, UT) ⤷  Try a Trial
NRX-101 ⤷  Try a Trial Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy Watson Laboratories, Inc. (Salt Lake City, UT) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for NRX-101

Drugname Country Document Number Estimated Expiration Related US Patent
NRX-101 Canada CA2973372 2035-01-09 ⤷  Try a Trial
NRX-101 European Patent Office EP3242659 2035-01-09 ⤷  Try a Trial
NRX-101 European Patent Office EP4122460 2035-01-09 ⤷  Try a Trial
NRX-101 World Intellectual Property Organization (WIPO) WO2016112263 2035-01-09 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.